Inhibitor eradication in refractory acquired hemophilia with lenalidomide

Ann Hematol. 2019 Jun;98(6):1533-1535. doi: 10.1007/s00277-019-03620-2. Epub 2019 Feb 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Autoantibodies / immunology
  • Autoimmune Diseases / complications
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / pathology
  • Drug Eruptions / etiology
  • Drug Substitution
  • Factor VIII / immunology
  • Hemophilia A / complications
  • Hemophilia A / drug therapy*
  • Hemophilia A / pathology
  • Hemorrhage / complications
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Lenalidomide / adverse effects
  • Lenalidomide / therapeutic use*
  • Male
  • Middle Aged
  • Paraplegia / etiology
  • Spinal Cord / blood supply

Substances

  • Autoantibodies
  • Immunosuppressive Agents
  • Factor VIII
  • Lenalidomide